glp-1 agonist therapy glp-1_analogs [TUSOM GLP-1 Therapy for Obesity Requires

Trending Now Find Similar Listings Account is under Review Comment posting is temporarily restricted

I have been long LLY and NVO because of GLP-1 drugs since early 2022, but as evidence continues to amass in favour of their utility for a large population its worth considering - what other implications does this have

Novo Nordisk foundation, Boehringer Ingelheim

Some, like Copaxone, are FDA-approved

The most common side effects from taking Semaglutide and Tirzepatide include, but are not limited to: Nausea, vomiting, diarrhea, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, hypotension, abdominal distension (bloating), eructation (burping), hypoglycemia in patients with type 2 diabetes, flatulence (gas), gastroenteritis, gastroesophageal reflux disease, injection site reactions, allergic reactions, and hair loss

[5] Talbott SM et al